Citius Pharmaceuticals receives Nasdaq delisting notice for failure to meet minimum bid price

Citius Pharmaceuticals has disclosed receipt of a deficiency notice from Nasdaq regarding its failure to maintain the minimum $1.00 bid price requirement. The company has 180 days to regain compliance, though the long-term impact on its capital structure and market access remains uncertain.